Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares saw an uptick in trading volume on Wednesday . 54,477 shares were traded during mid-day trading, an increase of 43% from the previous session's volume of 38,210 shares.The stock last traded at $11.09 and had previously closed at $10.82.
Analyst Ratings Changes
A number of research firms have recently weighed in on TLX. Wedbush reissued an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Finally, HC Wainwright began coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price target on the stock.
Get Our Latest Analysis on TLX
Telix Pharmaceuticals Stock Performance
The stock has a 50 day moving average price of $14.99 and a two-hundred day moving average price of $16.52. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.
Institutional Trading of Telix Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in TLX. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals during the 1st quarter worth $170,000. ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals during the 1st quarter worth $451,000. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth $297,000. Finally, Pier Capital LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter worth about $3,037,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access